Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 4Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Extranodal NK-T-Cell 2Neoplasm, Residual 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Down Syndrome 1

Interventions

zanubrutinib 1pegaspargase 1Rituximab 1Methylprednisolone 1Flow Cytometry 1Etoposide 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphohistiocytosis, Hemophagocytic × pegaspargase × Clear all
NCT07525466 2026-04-13

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Beijing Tongren Hospital

Phase 1/2 Recruiting
25 enrolled
LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡